GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zenotech Laboratories Ltd (BOM:532039) » Definitions » Debt-to-EBITDA

Zenotech Laboratories (BOM:532039) Debt-to-EBITDA : 0.00 (As of Mar. 2025)


View and export this data going back to 1996. Start your Free Trial

What is Zenotech Laboratories Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zenotech Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ₹0.0 Mil. Zenotech Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ₹0.0 Mil. Zenotech Laboratories's annualized EBITDA for the quarter that ended in Mar. 2025 was ₹196.5 Mil. Zenotech Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Zenotech Laboratories's Debt-to-EBITDA or its related term are showing as below:

During the past 13 years, the highest Debt-to-EBITDA Ratio of Zenotech Laboratories was 16.97. The lowest was -7.11. And the median was 0.73.

BOM:532039's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.71
* Ranked among companies with meaningful Debt-to-EBITDA only.

Zenotech Laboratories Debt-to-EBITDA Historical Data

The historical data trend for Zenotech Laboratories's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenotech Laboratories Debt-to-EBITDA Chart

Zenotech Laboratories Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.04 0.33 - - -

Zenotech Laboratories Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Zenotech Laboratories's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Zenotech Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zenotech Laboratories's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zenotech Laboratories's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Zenotech Laboratories's Debt-to-EBITDA falls into.


;
;

Zenotech Laboratories Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zenotech Laboratories's Debt-to-EBITDA for the fiscal year that ended in Mar. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 176.52
=0.00

Zenotech Laboratories's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 196.544
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2025) EBITDA data.


Zenotech Laboratories  (BOM:532039) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Zenotech Laboratories Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Zenotech Laboratories's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenotech Laboratories Business Description

Traded in Other Exchanges
N/A
Address
Survey No. 250-252, Turkapally Village, Shamirpet Mandal, RR District, Hyderabad, TG, IND, 500 078
Zenotech Laboratories Ltd is an India-based pharmaceutical company. It is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio primarily serves niche therapy areas like oncology and anesthesiology. It also manufactures products such as granulocyte-colony stimulating factor (GCSF) and Granulocyte-macrophage colony-stimulating factor (GMCSF). The company earns a vast majority of the revenue from the sale of its contract research and manufacturing services.

Zenotech Laboratories Headlines

No Headlines